Skip to content
Cultural Foundation
Author:
Medicus Pharma Ltd
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
September 10, 2026
Medicus Pharma Focuses on Precision Oncology and CD228V
September 8, 2026
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
August 3, 2026
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
July 31, 2026
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
July 27, 2026
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
July 16, 2026
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
June 22, 2026
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
June 15, 2026
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
June 11, 2026
1
2
3
Next Page
→